Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Salas, Maria Queralt  [Clear All Filters]
2024
Moya TAlfaro, Salas MQueralt, Carreira ASantos, Atenafu EG, Law ADatt, Lam W, Pasic I, Kim DDong Hwan, Michelis FV, Basso INovitzky, et al. Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies. Bone Marrow Transplant. 2024.
2023
Ruiz-Boy S, Pedraza A, Prat M, Salas MQueralt, Carcelero E, Riu-Viladoms G, Suárez-Lledó M, Monge-Escartín I, Rodríguez-Lobato LGerardo, Martínez-Roca A, et al. At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program. Pharmaceuticals (Basel). 2023;16(12).
Pedraza A, Salas MQueralt, Rodríguez-Lobato LGerardo, Escribano-Serrat S, Suárez-Lledó M, Martínez-Cebrian N, Solano MTeresa, Arcarons J, Rosiñol L, Gutiérrez-García G, et al. EASIX SCORE CORRELATES WITH ENDOTHELIAL DYSFUNCTION BIOMARKERS AND PREDICTS RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC TRANSPLANTATION. Transplant Cell Ther. 2023.
Palomo M, Moreno-Castaño ABelén, Salas MQueralt, Escribano-Serrat S, Rovira M, Guillen-Olmos E, Fernández S, Ventosa-Capell H, Youssef L, Crispi F, et al. Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications. Front Med (Lausanne). 2023;10:1285898.
Salas MQueralt, Pedraza A, Charry P, Suárez-Lledó M, Rodríguez-Lobato LGerardo, Brusosa M, Solano MTeresa, Serrahima A, Nomdedeu M, Cid J, et al. Post-transplant Cyclophosphamide and Tacrolimus for GVHD Prevention Allo-HCT from HLA-Matched Donors Generates more Advantages than Limitations. Transplant Cell Ther. 2023.
2022
Salas MQueralt, Charry P, Pedraza A, Martínez-Cibrián N, Solano MTeresa, Domenech A, Suárez-Lledó M, Nomdedeu M, Cid J, Lozano M, et al. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. Transplant Cell Ther. 2022.
2020
Salas MQueralt, Lam SChenc Wils, Pasic I, Gerbitz A, Michelis FV, Kim DDong Hwan, Al-Shaibani Z, Lipton JHoward, Mattsson J, Kumar R, et al. Less is More: Superior GVHD-Free/Relapse-Free Survival with Reduced Intensity Conditioning and Dual T-cell Depletion in AML. Biol Blood Marrow Transplant. 2020.
2019
Salas MQueralt, Prem S, Atenafu EG, Law ADatt, Lam W, Al-Shaibani Z, Loach D, Kim DDong Hwan, Michelis FV, Lipton JHoward, et al. Reduced Intensity Allogeneic Stem Cell Transplant with Anti-Thymocyte globulin and Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia. Eur J Haematol. 2019.
Salas MQueralt, Lam W, Law ADatt, Kim DDong Hwan, Michelis FV, Loach D, Al-Shaibani Z, Lipton JHoward, Kumar R, Mattsson J, et al. Reduced Intensity Conditioning Allogeneic Transplant with Dual T-cell Depletion in Myelofibrosis. Eur J Haematol. 2019.